TY - JOUR T1 - Randomised controlled, crossover trial to evaluate the effects of ambulatory oxygen on health status in patients with fibrotic lung disease JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2016.PA797 VL - 48 IS - suppl 60 SP - PA797 AU - Dina Visca AU - Sharon Fleming AU - Ashi Firouzi AU - Morag Farquhar AU - Nicholas Hopkinson AU - Charlotte Hogben AU - Winston Banya AU - Paul Cullinan AU - Angelo De Lauretis AU - Maria Kokosi AU - John Tayu Lee AU - Rosemarie Lyne AU - Sarah Agnew AU - Apollo Kwok AU - Surinder Birring AU - Alfredo Chetta AU - Anne Marie Russell AU - Peter Saunders AU - Toby Maher AU - Athol Wells AU - Lisa Spencer AU - Elisabetta Renzoni Y1 - 2016/09/01 UR - http://erj.ersjournals.com/content/48/suppl_60/PA797.abstract N2 - Breathlessness is a key determinant of Quality of life (QoL) in patients with fibrotic ILD. 6 minute walk test (6MWT) data indicates that a fall in oxygen saturation (SaO2) in ILD patients, can be corrected by supplemental O2. However, no prospective studies have assessed the impact of ambulatory O2 on QoL in patients with ILD.We report on a prospective, multi-centre trial (NCT02286063), investigating the effects of ambulatory O2 in fibrotic ILD patients. Design: a randomized, cross-over controlled trial evaluating QoL, breathlessness, and mobility during two weeks on ambulatory O2 compared to two weeks off O2 in 80 ILD patients. Inclusion: patients with SaO2 ≥ 94% at rest, on room air dropping to ≤88% on a 6MWT.Primary outcome: health status assessed by the King's Brief Interstitial Lung Disease Questionnaire. Key secondary outcomes: change in breathlessness and QoL scores (SGRQ, UCSDSBQ, HDAS), activity measurements and, in a subset, qualitative interviews.Interim Data patients randomized n=52, male n=37, mean age (± SD) of 64.5±1.1 yrs, ex-smokers n=36, mean FVC 69.3±18.4 %, and mean DLCO 38.7±12.8 %. Diagnosis: IIP n=31, CTD-ILD n=8, fibrotic HP n=6, miscellaneous n=7. All 45 patients that completed study wereoffered the option of continuing ambulatory O2.Conclusion: To date 35/45 (77.8%) patients have opted to continue with ambulatory O2 post study completion, suggesting the majority perceive that oxygen is beneficial. The final results of this study are expected to influence future ILD-specific guidelines for the use of ambulatory O2. ER -